Teruo Sawada

Present Position	Researcher
Qualification	Pharmacist
Education	April 1968 – March 1972: Osaka University April 1972 – March 1974: Department of Pharmacy, Graduate School of Osaka University

Professional Experience:	April 1974 – March 1999 Drug research institute and Drug Development Department of Kanebo Ltd. April 1999 – March 2008, Development Planning Department and Medical Affairs of Nippon Organon Ltd. November 2005 – October 2006 Project leader of Investigator-initiated clinical trial for Bepridil in Japan Medical Association April 2008 – June 2010, Director of Medical Affairs (Cardiovascular and Anesthesia), Schering-Plough Corporation July 2010 – January 2013, Manager of Medical Affairs (Cardiovascular, Anesthesia and Diabetes), MSD Ltd. March 2013 – present, Researcher of Department of Anatomy and Developmental Biology Graduate School of Medicine, Kyoto University

Professional
Experience:

April 1974 – March 1999
Drug research institute and Drug Development Department of Kanebo Ltd.
April 1999 – March 2008,
Development Planning Department and Medical Affairs of Nippon Organon Ltd.
November 2005 – October 2006
Project leader of Investigator-initiated clinical trial for Bepridil in Japan Medical Association
April 2008 – June 2010,
Director of Medical Affairs (Cardiovascular and Anesthesia), Schering-Plough Corporation
July 2010 – January 2013,
Manager of Medical Affairs (Cardiovascular, Anesthesia and Diabetes), MSD Ltd.
March 2013 – present,
Researcher of Department of Anatomy and Developmental Biology Graduate School of Medicine, Kyoto University

Selected publications	Kobayashi Y., Nakaya K., Sasai Y., Goto H., Takeyama Y., Kobayashi M., Katagiri T., Niitani H., Sawada T., Nakagawa H., Awata N.: Phase I study on a calcium antagonist, KB-944 [ Diethy 4-(benzothiazol-2-yl) benzylphosphonate ]. Japanese Pharmacology & Therapeutics 13, 2813-2827, 1985 Teramoto T., Sawada T., Iwamoto K., Daida H.: Clinical efficacy and tolerability of ezetimibe in combination with atorvastatin in Japanese patients with hypercholesterolemia – Ezetimibe phase IV randomized controlled trial in patients with hypercholesterolemia. Current Therapeutic Research 73, 16-40, 2012 Ajiro M., Sakai H., Onogi H., Yamamoto M., Sumi E., Sawada T., Nomura T., Kabashima K., Hosoya T., Hagiwara M. : CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia. Clinical Cancer Research 24, 4518-4528, 2018

Selected
publications

Kobayashi Y., Nakaya K., Sasai Y., Goto H., Takeyama Y., Kobayashi M., Katagiri T., Niitani H., Sawada T., Nakagawa H., Awata N.: Phase I study on a calcium antagonist, KB-944 [ Diethy 4-(benzothiazol-2-yl) benzylphosphonate ]. Japanese Pharmacology & Therapeutics 13, 2813-2827, 1985
Teramoto T., Sawada T., Iwamoto K., Daida H.: Clinical efficacy and tolerability of ezetimibe in combination with atorvastatin in Japanese patients with hypercholesterolemia – Ezetimibe phase IV randomized controlled trial in patients with hypercholesterolemia. Current Therapeutic Research 73, 16-40, 2012
Ajiro M., Sakai H., Onogi H., Yamamoto M., Sumi E., Sawada T., Nomura T., Kabashima K., Hosoya T., Hagiwara M. : CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia. Clinical Cancer Research 24, 4518-4528, 2018